Market Cap 1.44B
Revenue (ttm) 199.61M
Net Income (ttm) -17.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 91.15
Profit Margin -8.76%
Debt to Equity Ratio 0.78
Volume 527,500
Avg Vol 706,812
Day's Range N/A - N/A
Shares Out 37.00M
Stochastic %K 28%
Beta 0.27
Analysts Strong Sell
Price Target $67.91

Company Profile

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract sur...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 615 733 4730
Address:
1A Burton Hills Boulevard, Suite 200, Nashville, United States
sprk517
sprk517 Oct. 25 at 11:11 AM
$HROW Take a shot whenever @Finnish_boy says "SP $100 next year". 😆 (just some friendly banter)
1 · Reply
Finnish_boy
Finnish_boy Oct. 25 at 10:15 AM
$HROW Current SP has priced in VEVYE. Other drugs are bonus assets. IHEEZO, TRIESENCE, MELT-300, BIOSIMILARS, BYQLOVI, ImprimisRX whatever are free lunch. Lets see when there is fair market pricing. Some longs sell the stock because they know they can buy back lower due to manipulation and under radar status. Stock markets are not fair game. But time will heal this stock. We are close now. Q3 report can be the trigger. Next year $100 for sure.
0 · Reply
Finnish_boy
Finnish_boy Oct. 25 at 7:47 AM
$HROW This is my conservative road map. My best guess is that Q3 will be around 73-74M and stock heading to $50. Baum and Boll will be extremely bullish about outlook. Institutions will load up after Q3 report. New ATH this year, $70 is possible for sure. Next year $100. Easy money. Buying every potential dip. Market pricing doesnt work yet. SP need to double now. It wont though because under radar name.
1 · Reply
Fullback
Fullback Oct. 25 at 6:41 AM
$HROW Doing some noodling on H1 vs H2 sales and growth required to meet $280M guidance. Vevye must grow at least 50% from H1 to H2. IHEEZO must grow at least 14% from H1 to H2. Specialty Branded + 3E must grow at least 809% from H1 to H2. Imprimis RX can't shrink more than 8% from H1 to H2. That SB + 3e seems like a tall hill to climb % wise, but its coming off a small base...I'm hoping they achieve this...seems like this growth is all on 3e.
2 · Reply
Finnish_boy
Finnish_boy Oct. 24 at 9:43 PM
$HROW I use these estimates. I think SP hits new ATH this year and next year $100. Harrow has gained more and more analyst coverage and talented invidual investors so i am very confident price action going ahead. Markets pricing has to kick in. But if there was any bigger dip after Q3 report, i would go again all in. But i think SP heading to $50.
1 · Reply
Finnish_boy
Finnish_boy Oct. 24 at 8:21 PM
$HROW Short-sellers maybe try to play weak Q3 report. I think revenue will be 73-74M but revenue can be anything between 68-78m. If revenue would be 68-70m, you have to sell wife's jewellery for buying potential dip. But imo we dont have any dip because current SP doesnt price in anything. I think SP hits new ATH this year.
1 · Reply
Fullback
Fullback Oct. 24 at 8:14 PM
$HROW Almost 21% of the float short.
1 · Reply
Fullback
Fullback Oct. 24 at 8:12 PM
$HROW Bought again at $38.42, ~$1500 worth.
0 · Reply
Finnish_boy
Finnish_boy Oct. 24 at 7:10 PM
$HROW You can check short interest 16 pm ET https://www.nasdaqtrader.com/Trader.aspx?id=ShortInterest
1 · Reply
Finnish_boy
Finnish_boy Oct. 24 at 5:49 PM
$HROW Interesting short report after close.. lets see
1 · Reply
Latest News on HROW
ImprimisRx Announces Leadership Changes

Oct 6, 2025, 7:00 AM EDT - 19 days ago

ImprimisRx Announces Leadership Changes


Harrow, Inc. (HROW) Analyst/Investor Day Transcript

Sep 27, 2025, 12:27 AM EDT - 4 weeks ago

Harrow, Inc. (HROW) Analyst/Investor Day Transcript


Harrow to Acquire Melt Pharmaceuticals

Sep 26, 2025, 7:00 AM EDT - 4 weeks ago

Harrow to Acquire Melt Pharmaceuticals


Harrow Launches Harrow Access for All (HAFA)

Sep 25, 2025, 4:05 PM EDT - 4 weeks ago

Harrow Launches Harrow Access for All (HAFA)


Harrow Announces Agenda and Speakers for Investor & Analyst Day

Sep 15, 2025, 7:00 AM EDT - 5 weeks ago

Harrow Announces Agenda and Speakers for Investor & Analyst Day


Harrow: Buy A Blend Of Value And Growth

Sep 12, 2025, 10:57 AM EDT - 6 weeks ago

Harrow: Buy A Blend Of Value And Growth


Harrow: A Classical GARP Stock

Sep 9, 2025, 1:11 PM EDT - 6 weeks ago

Harrow: A Classical GARP Stock


Harrow's Ambitious Guidance Puts It In The Proving Ground

Aug 14, 2025, 11:09 PM EDT - 2 months ago

Harrow's Ambitious Guidance Puts It In The Proving Ground


Harrow: Exciting Times In Store

Aug 13, 2025, 5:39 PM EDT - 2 months ago

Harrow: Exciting Times In Store


Harrow, Inc. (HROW) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 2:47 PM EDT - 2 months ago

Harrow, Inc. (HROW) Q2 2025 Earnings Call Transcript


Harrow Announces Second-Quarter 2025 Financial Results

Aug 11, 2025, 4:01 PM EDT - 2 months ago

Harrow Announces Second-Quarter 2025 Financial Results


Harrow: Immense Upside Potential

Jul 9, 2025, 2:52 PM EDT - 3 months ago

Harrow: Immense Upside Potential


I Am Swimming In Dividends With +7% Yields

Jun 13, 2025, 8:30 AM EDT - 4 months ago

I Am Swimming In Dividends With +7% Yields

UMH


Harrow: Epic Growth & Operating Leverage On Full Display

May 28, 2025, 3:20 PM EDT - 5 months ago

Harrow: Epic Growth & Operating Leverage On Full Display


Harrow to Present at Two Investor Conferences in May

May 14, 2025, 7:00 AM EDT - 5 months ago

Harrow to Present at Two Investor Conferences in May


Harrow, Inc. (HROW) Q1 2025 Earnings Call Transcript

May 10, 2025, 6:17 PM EDT - 5 months ago

Harrow, Inc. (HROW) Q1 2025 Earnings Call Transcript


Harrow Announces First-Quarter 2025 Financial Results

May 8, 2025, 4:01 PM EDT - 6 months ago

Harrow Announces First-Quarter 2025 Financial Results


NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC.

Apr 24, 2025, 10:00 AM EDT - 6 months ago

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC.


Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)

Mar 29, 2025, 4:30 PM EDT - 7 months ago

Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)


Harrow, Inc. (HROW) Q4 2024 Earnings Conference Call

Mar 28, 2025, 2:00 PM EDT - 7 months ago

Harrow, Inc. (HROW) Q4 2024 Earnings Conference Call


Harrow Launches VEVYE® Access for All

Mar 17, 2025, 7:00 AM EDT - 7 months ago

Harrow Launches VEVYE® Access for All


Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

Jan 7, 2025, 7:00 AM EST - 10 months ago

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer


Those Derisked Baby Bonds Of Harrow, Inc.

Jan 3, 2025, 3:43 PM EST - 10 months ago

Those Derisked Baby Bonds Of Harrow, Inc.


Harrow: The Triesence Relaunch

Dec 14, 2024, 12:09 AM EST - 11 months ago

Harrow: The Triesence Relaunch


sprk517
sprk517 Oct. 25 at 11:11 AM
$HROW Take a shot whenever @Finnish_boy says "SP $100 next year". 😆 (just some friendly banter)
1 · Reply
Finnish_boy
Finnish_boy Oct. 25 at 10:15 AM
$HROW Current SP has priced in VEVYE. Other drugs are bonus assets. IHEEZO, TRIESENCE, MELT-300, BIOSIMILARS, BYQLOVI, ImprimisRX whatever are free lunch. Lets see when there is fair market pricing. Some longs sell the stock because they know they can buy back lower due to manipulation and under radar status. Stock markets are not fair game. But time will heal this stock. We are close now. Q3 report can be the trigger. Next year $100 for sure.
0 · Reply
Finnish_boy
Finnish_boy Oct. 25 at 7:47 AM
$HROW This is my conservative road map. My best guess is that Q3 will be around 73-74M and stock heading to $50. Baum and Boll will be extremely bullish about outlook. Institutions will load up after Q3 report. New ATH this year, $70 is possible for sure. Next year $100. Easy money. Buying every potential dip. Market pricing doesnt work yet. SP need to double now. It wont though because under radar name.
1 · Reply
Fullback
Fullback Oct. 25 at 6:41 AM
$HROW Doing some noodling on H1 vs H2 sales and growth required to meet $280M guidance. Vevye must grow at least 50% from H1 to H2. IHEEZO must grow at least 14% from H1 to H2. Specialty Branded + 3E must grow at least 809% from H1 to H2. Imprimis RX can't shrink more than 8% from H1 to H2. That SB + 3e seems like a tall hill to climb % wise, but its coming off a small base...I'm hoping they achieve this...seems like this growth is all on 3e.
2 · Reply
Finnish_boy
Finnish_boy Oct. 24 at 9:43 PM
$HROW I use these estimates. I think SP hits new ATH this year and next year $100. Harrow has gained more and more analyst coverage and talented invidual investors so i am very confident price action going ahead. Markets pricing has to kick in. But if there was any bigger dip after Q3 report, i would go again all in. But i think SP heading to $50.
1 · Reply
Finnish_boy
Finnish_boy Oct. 24 at 8:21 PM
$HROW Short-sellers maybe try to play weak Q3 report. I think revenue will be 73-74M but revenue can be anything between 68-78m. If revenue would be 68-70m, you have to sell wife's jewellery for buying potential dip. But imo we dont have any dip because current SP doesnt price in anything. I think SP hits new ATH this year.
1 · Reply
Fullback
Fullback Oct. 24 at 8:14 PM
$HROW Almost 21% of the float short.
1 · Reply
Fullback
Fullback Oct. 24 at 8:12 PM
$HROW Bought again at $38.42, ~$1500 worth.
0 · Reply
Finnish_boy
Finnish_boy Oct. 24 at 7:10 PM
$HROW You can check short interest 16 pm ET https://www.nasdaqtrader.com/Trader.aspx?id=ShortInterest
1 · Reply
Finnish_boy
Finnish_boy Oct. 24 at 5:49 PM
$HROW Interesting short report after close.. lets see
1 · Reply
mutallim
mutallim Oct. 24 at 5:44 PM
$PGY $DLO $HROW time to start
0 · Reply
sprk517
sprk517 Oct. 24 at 2:09 PM
$HROW Anyone eyeing or owning some calls? April '26 and Jan '27 could be interesting. Q4 '25 results and '26 outlook could be a decent catalyst.
1 · Reply
Alberthansson02
Alberthansson02 Oct. 24 at 2:05 PM
$HROW where is the volume?!
2 · Reply
Clarkkent89
Clarkkent89 Oct. 24 at 1:37 PM
$HROW Selling names that are pumping to buy more of HROW here
0 · Reply
Fullback
Fullback Oct. 23 at 10:31 PM
$HROW A little over 1/3 the avg volume today.....light!
0 · Reply
Fullback
Fullback Oct. 22 at 7:23 PM
$HROW Added ~ 40 shares at $38.60.
1 · Reply
Finnish_boy
Finnish_boy Oct. 22 at 10:55 AM
$HROW I want to remind that ImprismisRX is best in class in eye compounded business. Recalls are totally normal for compounded business. The California case is mostly FUD and just coincidence considering the timing of CEO change. Quality team the behind of quality, not CEO. Harrow has recruited two talented quality experts this year. CEO change had been prepared for long time imho. ImprimisRX is doing awesome.
2 · Reply
Fullback
Fullback Oct. 21 at 10:06 PM
$HROW The more I think about the ImprimisRx fiasco, JS was a sales guy, not an operational guy. Not the right guy for the right job. Thus the repetitive violations and mis steps. Surprised MB couldn't recognize this due to his proximity to JS. New folks will clean this up I bet I'll be expecting better compliance results.
3 · Reply
Tennis_4567
Tennis_4567 Oct. 21 at 4:59 PM
$HROW super low volume here on a little pullback which is nice to see. Unless there’s a catalyst in the next few weeks I’d expect this to trade sideways until earnings. Next short report out Friday
0 · Reply
Fullback
Fullback Oct. 20 at 11:13 PM
$HROW About 4/5 Avg 90 day volume today along with a nice SP increase. Interesting to see how this trades as Q3 CC approaches.
1 · Reply
tupelo3
tupelo3 Oct. 20 at 5:57 PM
$HROW Can someone tell me what analyst estimates for iheezo peak sales are?
6 · Reply
Fullback
Fullback Oct. 18 at 3:21 AM
$HROW Trading volume has really picked up on $HROW Google Finance's 30 day average: Yahoo's 90 day average:
1 · Reply